The design, synthesis and pharmacological characterization of novel β 2-adrenoceptor antagonists

British Journal of Pharmacology

Volumn 164, Issue 2, 2011, Pages 317-331

  Hothersall, J Daniel ^a   Black, James ^b   Caddick, Stephen ^a   Vinter, Jeremy G ^c   Tinker, Andrew ^a   Baker, James R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Cresset BioMolecular Discovery Ltd   (United Kingdom)

Author keywords

adrenoceptor; antagonist; cell signalling

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ATENOLOL; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CARAZOLOL; CYANOPINDOLOL; JB 141; JB 142; JB 143; JB 163; JB 175; JB 176; PROPRANOLOL; SALBUTAMOL; T 0502 1048; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; ENANTIOMER; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLIC AMP; DRUG DESIGN; FEMALE; GUINEA PIGS; MALE; MODELS, MOLECULAR; PROPANOLAMINES; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRACHEA;

EID: 80052001781     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01269.x     Document Type: Article

References (57)

1. Affolter H, Hertel C, Jaeggi K, Portenier M, Staehelin M, (1985). (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci U S A 82: 925-929. (Pubitemid 15142790)
2. Alewijnse AE, Smit MJ, Rodriguez Pena MS, Verzijl D, Timmerman H, Leurs R, (1997). Modulation of forskolin-mediated adenylyl cyclase activation by constitutively active G(S)-coupled receptors. FEBS Lett 419: 171-174. (Pubitemid 28010804)
3. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-254.
4. Audet M, Bouvier M, (2008). Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol 4: 397-403. (Pubitemid 351860553)
5. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al,. (2003). Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 100: 11406-11411. (Pubitemid 37205948)
6. Baker JG, (2005). The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144: 317-322. (Pubitemid 40313677)
7. Baker JG, Hall IP, Hill SJ, (2003a). Agonist actions of 'beta-blockers' provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol 63: 1312-1321. (Pubitemid 36627226)
8. Baker JG, Hall IP, Hill SJ, (2003b). Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64: 1357-1369. (Pubitemid 37532226)
9. Baker JR, Hothersall JD, Fitzmaurice RJ, Tucknott M, Vinter A, Tinker A, et al,. (2010). An efficient asymmetric synthesis of the potent beta-blocker ICI-118,551 allows the determination of enantiomer dependency on biological activity. Chem Commun 46: 3953-3954.
10. Bilski AJ, Halliday SE, Fitzgerald JD, Wale JL, (1983). The pharmacology of a beta 2-selective adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol 5: 430-437. (Pubitemid 13080761)
11. Carswell H, Nahorski SR, (1983). Beta-adrenoceptor heterogeneity in guinea-pig airways: comparison of functional and receptor labelling studies. Br J Pharmacol 79: 965-971. (Pubitemid 13025899)
12. Cejas MA, Kinney WA, Chen C, Vinter JG, Almond HR Jr, Balss KM, et al,. (2008). Thrombogenic collagen-mimetic peptides: self-assembly of triple helix-based fibrils driven by hydrophobic interactions. Proc Natl Acad Sci U S A 105: 8513-8518. (Pubitemid 351987711)
13. Cheeseright T, Mackey M, Rose S, Vinter A, (2006). Molecular field extrema as descriptors of biological activity: definition and validation. J Chem Inf Model 46: 665-676.
14. Cheeseright TJ, Mackey MD, Melville JL, Vinter JG, (2008). FieldScreen: virtual screening using molecular fields. Application to the DUD data set. J Chem Inf Model 48: 2108-2117.
15. Cheng Y, Prusoff WH, (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
16. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al,. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265. (Pubitemid 350172884)
17. Chessari G, Hunter CA, Low CM, Packer MJ, Vinter JG, Zonta C, (2002). An evaluation of force-field treatments of aromatic interactions. Chemistry 8: 2860-2867. (Pubitemid 34778590)
18. Christopoulos A, Kenakin T, (2002). G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54: 323-374. (Pubitemid 34575719)
19. CIBIS Investigators and Committees (1994). A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 90: 1765-1773.
20. 2-adrenergic receptor to different G proteins by protein kinase A. 88-91.
21. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ, (2008). beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283: 5669-5676.
22. Fitzgerald JD, (1991). The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes. Cardiovasc Drugs Ther 5: 561-576.
23. Ghosh K, Kowal D, Dawson LA, Tasse R, (1999). Design and models for estimating antagonist potency (pA2, Kd and IC50) following the detection of antagonism observed in the presence of intrinsic activity. Neuropharmacology 38: 361-373. (Pubitemid 29097719)
24. Giblin JP, Leaney JL, Tinker A, (1999). The molecular assembly of ATP-sensitive potassium channels: determinants on the pore forming subunit. J Biol Chem 274: 22652-22659.
25. Gong H, Sun H, Koch WJ, Rau T, Eschenhagen T, Ravens U, et al,. (2002). Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart. Circulation 105: 2497-2503. (Pubitemid 34568971)
26. Harding SE, Gong H, (2004). beta-adrenoceptor blockers as agonists: coupling of beta2-adrenoceptors to multiple G-proteins in the failing human heart. Congest Heart Fail 10: 181-185.
27. Hopkinson HE, Latif ML, Hill SJ, (2000). Non-competitive antagonism of beta(2)-agonist-mediated cyclic AMP accumulation by ICI 118551 in BC3H1 cells endogenously expressing constitutively active beta(2)-adrenoceptors. Br J Pharmacol 131: 124-130.
28. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ, (2004). Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol 369: 525-532. (Pubitemid 38669972)
29. Keith RA, Donahue JY, Salama AI, (1986). The effect of varying carbachol concentration on the slope of Schild plots of selective beta-adrenoceptor antagonists in the carbachol-contracted guinea-pig trachea. J Pharm Pharmacol 38: 107-112. (Pubitemid 16146063)
30. Kenakin T, (1997). Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trens Pharmacol Sci 18: 456-464. (Pubitemid 28051762)
31. Kenakin T, (2004). Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65: 2-11. (Pubitemid 38113879)
32. Kenakin TP, (2006). A Pharmacology Primer: Theory, Applications and Methods, 2nd edn. Academic Press: San Diego, CA.
33. Kolb P, Rosenbaum DM, Irwin JJ, Fung JJ, Kobilka BK, Shoichet BK, (2009). Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U S A 106: 6843-6848.
34. McGuinness D, Malikzay A, Visconti R, Lin K, Bayne M, Monsma F, et al,. (2009). Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assay. J Biomol Screen 14: 49-58.
35. MERIT-HF Study Group (1999). Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007.
36. Mikami M, Goubaeva F, Song JH, Lee HT, Yang J, (2008). beta-Adrenoceptor blockers protect against staurosporine-induced apoptosis in SH-SY5Y neuroblastoma cells. Eur J Pharmacol 589: 14-21.
37. Morris TH, Kaumann AJ, (1984). Different steric characteristics of beta 1- and beta 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 327: 176-179. (Pubitemid 14066546)
38. O'Donnell SR, Wanstall JC, (1979). The importance of choice of agonist in studies designed to predict beta 2: beta 1 adrenoceptor selectivity of antagonists from pA2 values on guinea-pig trachea and atria. Naunyn Schmiedebergs Arch Pharmacol 308: 183-190. (Pubitemid 10196308)
39. O'Donnell SR, Wanstall JC, (1980). Are the pA2 values of selective beta-adrenoceptor antagonists valid when obtained on guinea-pig tracheal preparations contracted with carbachol? J Pharm Pharmacol 32: 413-416. (Pubitemid 10021910)
40. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al,. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334: 1349-1355. (Pubitemid 26152713)
41. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al,. (2003). Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7-13. (Pubitemid 36835815)
42. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, et al,. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-387. (Pubitemid 350126755)
43. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, et al,. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318: 1266-1273. (Pubitemid 350172885)
44. Salomon Y, (1991). Cellular responsiveness to hormones and neurotransmitters: conversion of [3H]adenine to [3H]cAMP in cell monolayers, cell suspensions, and tissue slices. In:, Johnson RA, Corbin JD, (eds.). Methods in Enzymology. Academic Press: New York, pp. 22-28.
45. Sutkowski EM, Tang WJ, Broome CW, Robbins JD, Seamon KB, (1994). Regulation of forskolin interactions with type I, II, V, and VI adenylyl cyclases by Gs alpha. Biochemistry 33: 12852-12859. (Pubitemid 24352876)
46. Tanaka Y, Yamashita Y, Horinouchi T, Koike K, (2005). Adrenaline produces the relaxation of guinea-pig airway smooth muscle primarily through the mediation of beta(2)-adrenoceptors. J Smooth Muscle Res 41: 153-161. (Pubitemid 41373395)
47. Tanaka Y, Yamashita Y, Michikawa H, Horinouchi T, Koike K, (2007). Pharmacological characterization of the beta-adrenoceptor that mediates the relaxant response to noradrenaline in guinea-pig tracheal smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 375: 51-64. (Pubitemid 46354556)
48. Teixeira CE, Baracat JS, Zanesco A, Antunes E, De NG, (2004). Atypical beta-adrenoceptor subtypes mediate relaxations of rabbit corpus cavernosum. J Pharmacol Exp Ther 309: 587-593. (Pubitemid 38542611)
49. Vinter JG, (1994). Extended electron distributions applied to the molecular mechanics of some intermolecular interactions. J Comput Aided Mol Des 8: 653-668.
50. Wacker D, Fenalti G, Brown MA, Katritch V, Abagyan R, Cherezov V, et al,. (2010). Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc 132: 11443-11445.
51. Wahlund G, Nerme V, Abrahamsson T, Sjoquist PO, (1990). The beta 1- and beta 2-adrenoceptor affinity and beta 1-blocking potency of S- and R-metoprolol. Br J Pharmacol 99: 592-596. (Pubitemid 20069169)
52. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, et al,. (2008). Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
53. Wenzel D, Knies R, Matthey M, Klein AM, Welschoff J, Stolle V, et al,. (2009). beta(2)-adrenoceptor antagonist ICI 118,551 decreases pulmonary vascular tone in mice via a G(i/o) protein/nitric oxide-coupled pathway. Hypertension 54: 157-163.
54. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al,. (2007). A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 104: 16657-16662. (Pubitemid 350211072)
55. Woo AY, Wang TB, Zeng X, Zhu W, Abernethy DR, Wainer IW, et al,. (2009). Stereochemistry of an agonist determines coupling preference of 2-adrenoceptor to different g proteins in cardiomyocytes. Mol Pharmacol 75: 158-165.
56. Zamah AM, Delahunty M, Luttrell LM, Lefkowitz RJ, (2002). Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system. J Biol Chem 277: 31249-31256. (Pubitemid 34970833)
57. Zheng M, Zhu W, Han Q, Xiao RP, (2005). Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol Ther 108: 257-268. (Pubitemid 41691867)